Nation

Jiangsu Hengrui Set to Raise $1.27 Billion with Hong Kong Listing!

2025-05-21

Author: Ming

A Major Player in Pharma Takes the Stage

Jiangsu Hengrui Pharmaceuticals, a leading Chinese drug developer, is making a splash in the financial world with an impressive Hong Kong listing. Pricing its shares at HK$44.05 ($5.63), the company is set to raise a whopping $1.27 billion.

Details of the Deal

The Shanghai-listed pharmaceutical giant has sold 224.5 million shares, falling at the top end of its price range that spanned from HK$41.45 to HK$44.05. This strategic pricing showcases the high demand for Hengrui’s stock.

Cornerstone Investors Back the Move

In a show of confidence, seven cornerstone investors, including Singapore’s prominent sovereign wealth fund GIC, have backed the deal, committing around $533 million in total. Notably, GIC alone is investing approximately $268 million.

Trading Set to Commence

Hengrui’s shares are anticipated to begin trading on the Hong Kong Stock Exchange this Friday, marking a significant milestone for the company.

A Rising Trend in Chinese Listings

This major listing comes on the heels of another significant event in the market: Chinese battery titan CATL recently raised $5.3 billion in what has been dubbed the largest global listing of 2025. This trend highlights the growing interest and confidence in Chinese firms listing on international exchanges.

As Jiangsu Hengrui prepares to enter the trading spotlight, all eyes will be on this pharmaceutical powerhouse to see how it performs on the global stage.